Evaluation of Patients Suffering From Polytrauma Admitted to the ICU (Polytrauma ICU)

March 16, 2026 updated by: Stessel Björn, Jessa Hospital

Evaluation of Patients Suffering From Polytrauma Admitted to the ICU: a Retrospective Cohort Study.

The primary objective of this study is to assess the number of polytrauma patients admitted to the Intensive Care Unit. In addition, we aim to describe their clinical characteristics, therapeutic management, and clinical outcomes.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Trauma constitutes a major contributor to global mortality and long-term physical disability. The principal causes of traumatic injury include road traffic accidents, falls, drowning, burns, poisoning, interpersonal violence, and acts of war. Collectively, these causes account for approximately 9% of global deaths.

Within the broader population of trauma patients, polytrauma patients represent a distinct and clinically significant subgroup, accounting for approximately 25% of trauma-related hospital admissions. Polytrauma is not merely defined as the coexistence of multiple injuries, but rather as a complex clinical condition characterized by a high risk of complications and progressive physiological deterioration. In the early post-traumatic phase, patients may develop severe hemorrhage, hemorrhagic shock, respiratory compromise, or traumatic brain injury. In the subsequent phase, systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction syndrome may occur.

Advances in injury prevention strategies and improvements in trauma care have led to increased survival during the early stages following injury. As a result, a growing number of polytrauma patients require admission to the Intensive Care Unit (ICU), underscoring the need to optimize critical care delivery in this population. The provision of high-quality, evidence-based care depends on the systematic collection and analysis of comprehensive clinical data to facilitate continuous improvement in treatment strategies and outcomes.

Study Type

Observational

Enrollment (Estimated)

417

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Hasselt, Belgium, 3500
        • Jessa Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

Description

Inclusion Criteria:

  • All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

Exclusion Criteria:

  • Younger than 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: through study completion, an average of 1 year.
All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025
through study completion, an average of 1 year.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of stay
Time Frame: through study completion, an average of 1 year.
The length of stay at ICU and hospital of all patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025
through study completion, an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jessa Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 10, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

February 23, 2026

First Submitted That Met QC Criteria

March 16, 2026

First Posted (Actual)

March 19, 2026

Study Record Updates

Last Update Posted (Actual)

March 19, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025/039

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polytrauma Patients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe